Pranlukast: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
m Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)
 
(21 intermediate revisions by 16 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Infobox drug
| Watchedfields = changed
| verifiedrevid = 464213227
| verifiedrevid = 464213227
| IUPAC_name = ''N''-[4-oxo-2-(1''H''-tetrazol-5-yl)-4''H''-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
| IUPAC_name = ''N''-[4-oxo-2-(1''H''-tetrazol-5-yl)-4''H''-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
Line 13: Line 15:
<!--Pharmacokinetic data-->
<!--Pharmacokinetic data-->
| bioavailability =
| bioavailability =
| metabolism = [[Liver|Hepatic]] (mainly [[CYP3A4]])<ref name = Nakade>{{cite journal | author = Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S | title = Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma. | journal = Drug Metab Pharmacokinet | volume = 21 | issue = 2 | pages = 133–9 | year = 2006 | pmid = 16702733 | url = http://www.jstage.jst.go.jp/article/dmpk/21/2/21_133/_article | doi = 10.2133/dmpk.21.133}}</ref>
| metabolism = [[Liver|Hepatic]] (mainly [[CYP3A4]])<ref name=Nakade>{{cite journal | vauthors = Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S | title = Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma | journal = Drug Metabolism and Pharmacokinetics | volume = 21 | issue = 2 | pages = 133–139 | date = April 2006 | pmid = 16702733 | doi = 10.2133/dmpk.21.133 | url = http://www.jstage.jst.go.jp/article/dmpk/21/2/21_133/_article | url-status = dead | archive-url = https://web.archive.org/web/20080917120315/http://www.jstage.jst.go.jp/article/dmpk/21/2/21_133/_article | archive-date = 2008-09-17 }}</ref>
| elimination_half-life = 1.5 hours<ref name = Nakade/>
| elimination_half-life = 1.5 hours<ref name = Nakade/>
| excretion =
| excretion =
Line 35: Line 37:
<!--Chemical data-->
<!--Chemical data-->
| C=27 | H=23 | N=5 | O=4
| C=27 | H=23 | N=5 | O=4
| smiles = O=C(Nc2cccc3c(=O)cc(c1nn[nH]n1)oc23)c5ccc(OCCCCc4ccccc4)cc5
| molecular_weight = 481.503 g/mol
| smiles = O=C(c2ccc(OCCCCc1ccccc1)cc2)Nc5cccc3c5O/C(=C\C3=O)c4nnnn4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
| StdInChI = 1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
Line 44: Line 45:
'''Pranlukast''' (brand name '''Onon''', '''オノン''') is a cysteinyl [[Leukotriene receptor antagonist|leukotriene receptor-1 antagonist]]. This drug works similarly to [[Merck & Co.]]'s [[montelukast]] (Singulair). It is widely used in Japan.
'''Pranlukast''' (brand name '''Onon''', '''オノン''') is a cysteinyl [[Leukotriene receptor antagonist|leukotriene receptor-1 antagonist]]. This drug works similarly to [[Merck & Co.]]'s [[montelukast]] (Singulair). It is widely used in Japan.


Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of [[bronchospasm]] caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered [[allergen]]s.
Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of [[bronchospasm]] caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered [[allergen]]s.<ref name="SinghTandon2013">{{cite journal | vauthors = Singh RK, Tandon R, Dastidar SG, Ray A | title = A review on leukotrienes and their receptors with reference to asthma | journal = The Journal of Asthma | volume = 50 | issue = 9 | pages = 922–931 | date = November 2013 | pmid = 23859232 | doi = 10.3109/02770903.2013.823447 | s2cid = 11433313 }}</ref>


Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled [[Long acting beta-adrenoceptor agonist|long-]] and/or short-acting [[Beta2-adrenergic receptor agonist|beta-agonist]]s. There are several similar medications in the group; all appear to be equally effective.
Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled [[Long acting beta-adrenoceptor agonist|long-]] and/or short-acting [[Beta2-adrenergic receptor agonist|beta-agonist]]s. There are several similar medications in the group; all appear to be equally effective. Pranlukast is also reported as potential inhibitor of Mycobacterium tuberculosis infection in experimental models.<ref name="Mishra A 2018">{{cite journal | vauthors = Mishra A, Mamidi AS, Rajmani RS, Ray A, Roy R, Surolia A | title = An allosteric inhibitor of ''Mycobacterium tuberculosis'' ArgJ: Implications to a novel combinatorial therapy | journal = EMBO Molecular Medicine | volume = 10 | issue = 4 | pages = e8038 | date = April 2018 | pmid = 29483133 | pmc = 5887547 | doi = 10.15252/emmm.201708038 }}</ref>


==References==
== References ==


{{Reflist|2}}
{{Reflist|2}}



{{Asthma and copd rx}}
{{Asthma and copd rx}}
Line 59: Line 59:
[[Category:Tetrazoles]]
[[Category:Tetrazoles]]
[[Category:Chromones]]
[[Category:Chromones]]
[[Category:Drugs developed by Merck & Co.]]
[[Category:Benzamides]]
[[Category:Benzamides]]
[[Category:Phenol ethers]]
[[Category:Phenol ethers]]

Latest revision as of 13:14, 9 January 2024

Pranlukast
Clinical data
Trade namesOnon (オノン)
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Pharmacokinetic data
MetabolismHepatic (mainly CYP3A4)[1]
Elimination half-life1.5 hours[1]
Identifiers
  • N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-8-yl]-4-(4-phenylbutoxy)benzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.236.084 Edit this at Wikidata
Chemical and physical data
FormulaC27H23N5O4
Molar mass481.512 g·mol−1
3D model (JSmol)
  • O=C(Nc2cccc3c(=O)cc(c1nn[nH]n1)oc23)c5ccc(OCCCCc4ccccc4)cc5
  • InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32) checkY
  • Key:NBQKINXMPLXUET-UHFFFAOYSA-N checkY
  (verify)

Pranlukast (brand name Onon, オノン) is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s montelukast (Singulair). It is widely used in Japan.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.[2]

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective. Pranlukast is also reported as potential inhibitor of Mycobacterium tuberculosis infection in experimental models.[3]

References[edit]

  1. ^ a b Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S (April 2006). "Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma". Drug Metabolism and Pharmacokinetics. 21 (2): 133–139. doi:10.2133/dmpk.21.133. PMID 16702733. Archived from the original on 2008-09-17.
  2. ^ Singh RK, Tandon R, Dastidar SG, Ray A (November 2013). "A review on leukotrienes and their receptors with reference to asthma". The Journal of Asthma. 50 (9): 922–931. doi:10.3109/02770903.2013.823447. PMID 23859232. S2CID 11433313.
  3. ^ Mishra A, Mamidi AS, Rajmani RS, Ray A, Roy R, Surolia A (April 2018). "An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy". EMBO Molecular Medicine. 10 (4): e8038. doi:10.15252/emmm.201708038. PMC 5887547. PMID 29483133.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Pranlukast&oldid=1194533728"